Journals / Genel Tıp Dergisi / 2004 / Cilt: 14 - Sayı: 4

Evaluation of the effect of hormone replacement therapy on cardiovascular functions with new parameters

Hormon replasman tedavisinin kardiyak fonksiyonlar üzerine etkisinin yeni parametrelerle değerlendirilmesi

Pages
145–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Long term, wide spectrum randomized studies are needed to expose whether this improvement trend will be significant or not.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cardiovascular system is one of the most affected system in menopause.
📊
Key Findings & Data:Methods: Thirty-seven patients given HRT were taken as study group and 32 healthy postmenopausal women were taken as control group.
💡
Conclusion & Impact:Long term, wide spectrum randomized studies are needed to expose whether this improvement trend will be significant or not.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hormon replasman tedavisi · Postmenopoz · Diyastol

Abstract

Objective: Cardiovascular system is one of the most affected system in menopause. It is aimed to investigate the effects of HRT on cardiovascular functions in healthy postmenopausal women. Methods: Thirty-seven patients given HRT were taken as study group and 32 healthy postmenopausal women were taken as control group. Standard echocardiography were performed to all cases. Sequentially, systolic and diastolic time intervals were measured with pulsed wave tissue Doppler and myocardial performance index was calculated. The same parameters obtained after 3 months of HRT and compared with the basal values. Results: There was no change at left ventricle (LV) segmental systolic myocardial velocity (Sm) and tricuspid Sm values after 3 months according to basal values in both groups. While the mean early myocardial velocity (Em) of LV increased, late myocardial velocity (Am) decreased and Em/Am ratio increased in HRT group. In addition it was determined that the mitral early inflow velocity/late inflow velocity ratio increased. Mean LV myocardial performance index was also decreased after the 3 months of HRT. Nevertheless, these changes could not reach to a statistically significance. Conclusion: Although it is not significant, HRT may cause improvement in LV diastolic function. Long term, wide spectrum randomized studies are needed to expose whether this improvement trend will be significant or not.

Özet

Amaç: Menopoz nedeniyle meydana gelen değişikliklerden en çok etkilenen sistemlerden biri de kardiyovasküler sistemdir. Bu çalışma, sağlıklı postmenopozal kadınlarda HRT´nin kardiyak fonksiyonlar üzerine etkilerinin yeni parametreler kullanılarak değerlendirilmesi amacıyla planlanmıştır. Yöntem: Çalışmaya HRT uygulanacak 35 ve kontrol grubu olarak da aynı özelliklere sahip 32 sağlıklı postmenopozal kadın alındı. Tüm bireylere standart ekokardiyografi yapıldı. Ardından doku Doppler pulsed wave yöntemi uygulanarak miyokardiyal hızlar ile sistolik ve diyastolik zaman intervalleri ölçülerek miyokard performans indeksi (MPİ) hesaplandı. Üç ay sonra elde edilen parametreler, bazal değerlerle karşılaştırıldı. Bulgular: Sol ventrikül (SV) segmenter sistolik miyokardiyal hız (Sm), ortalama Sm ve triküspit Sm değerlerinde her iki grupta da 3 ay sonra değişiklik tespit edilemedi. HRT grubunda SV için ortalama erken miyokardiyal hızı (Em) artarken geç miyokardiyal hız (Am) azaldı. Em/Am oranı ve mitral erken diyastolik doluş hızı/mitral geç diyastolik hızı oranı arttı. MPİ değerlerinde HRT alan grupta üç ay sonra azalma eğilimi vardı. Fakat bu değişiklikler istatistiki anlamlılığa ulaşmadı. Sonuç: Anlamlı olmasa da, 3 ay süreli HRT özellikle SV diyastolik fonksiyonlarında düzelmeye neden olabilir. Bu düzelme eğiliminin anlamlı olup olmadığının ortaya çıkarılması için uzun süreli geniş katılımlı randomize çalışmalara ihtiyaç vardır.

🔖

Cite This Article

DÜZENLİ, M. A., ÖZDEMİR, K., SÖKMEN, A., ÇELİK, Ç., SOYLU, A., GEZGİNÇ, K., YAZICI, M., ALTUNKESER, B. B., GÖK, H. (2004). Evaluation of the effect of hormone replacement therapy on cardiovascular functions with new parameters. Genel Tıp Dergisi, Cilt: 14 - Sayı: 4, 145–152. https://ajindex.com/articles/225031

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ertungealp E, Seyisoğlu H. Klimakteryum ve menopoz. İçinde: Kisnişci, Gökşin editörler. Temel Kadın Hastalıkları ve Doğum Bilgisi. Ankara, Güneş Kitabevi, 1996; 1331-46
  2. Gorodeski G, Ution WH. Epidemiology and risk factors of cardiovascular disease in postmenopausal women. In: Lobo RA, ed. Treatment of postmenopausal women. New York: Rawen Press; 1994. 12-32
  3. Hendersen BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-18
  4. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
  5. Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995;49:87-90
  6. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002;89 (suppl): 12E- 18E
  7. The Writing group for the PEPI trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopozal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208
  8. Koh KK, Mincemoyer R, Bul MN, Csako G, Pucino F, Guetta V, et al. Effect of hormone replacement therapy on fibrinolysis in postmenopausal women. N Eng J Med 1997;336:693-690
  9. Hulley S, Grady P, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopozal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
  10. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcome during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002;288:49-57
  11. Writing group for the Women´s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopozal women. Principal results from the Women´s Health Initiative randomised controlled trial. JAMA 2002;288:321-33
  12. Pines A, Fisman EZ, Shemesh J, Levo Y, Ayalon D, Kellermann JJ, et al. Menopause-related changes in left ventricular function in healthy women. Cardiology 1992; 80:413-6
  13. Prelevic GM, Beljie T. The effect of estrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 1994;20:37-44
  14. Pines A, Fisman EZ, Levo Y, Drory D, Ben-Ari E, Motro M, et al